share_log

和鉑醫藥-B：2023 環境、社會及管治報告

HBM HOLDINGS-B: Environmental, Social and Governance Report 2023

Hong Kong Stock Exchange ·  Apr 24 19:11
Summary by Moomoo AI
和鉑醫藥-B（02142.HK）於2024年3月28日通過其第四份環境、社會及管治（ESG）報告，展示了公司在2023年在社會責任、環境保護和公司治理方面的努力與成果。報告顯示，和鉑醫藥在面對困難的外部環境下，仍專注於腫瘤及免疫性疾病領域的創新藥研發及商業化，並通過多元化的合作模式拓展其核心技術平台的全球應用。公司持續推動ESG理念融入經營戰略，並在保持高速增長的同時，積極履行社會與環境責任。報告中亦提到了和鉑醫藥在治理、員工權益、環境保護、創新研發、供應鏈管理等方面的具體措施和成效，包括對員工的培訓、健康保障、薪酬福利，以及對供應商的環境及社會風險管理。此外，公司也在應對氣候變化方面做出了承諾，並設立了相關的管理目標和措施。
和鉑醫藥-B（02142.HK）於2024年3月28日通過其第四份環境、社會及管治（ESG）報告，展示了公司在2023年在社會責任、環境保護和公司治理方面的努力與成果。報告顯示，和鉑醫藥在面對困難的外部環境下，仍專注於腫瘤及免疫性疾病領域的創新藥研發及商業化，並通過多元化的合作模式拓展其核心技術平台的全球應用。公司持續推動ESG理念融入經營戰略，並在保持高速增長的同時，積極履行社會與環境責任。報告中亦提到了和鉑醫藥在治理、員工權益、環境保護、創新研發、供應鏈管理等方面的具體措施和成效，包括對員工的培訓、健康保障、薪酬福利，以及對供應商的環境及社會風險管理。此外，公司也在應對氣候變化方面做出了承諾，並設立了相關的管理目標和措施。
AND PLATINUM PHARMACEUTICAL-B (02142.HK) PASSED ITS FOURTH ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT ON MARCH 28, 2024, SHOWCASING THE COMPANY'S EFFORTS AND ACHIEVEMENTS IN SOCIAL RESPONSIBILITY, ENVIRONMENTAL PROTECTION AND CORPORATE GOVERNANCE IN 2023. The report shows that in the face of a difficult external environment, Platinum Pharmaceuticals remains focused on innovative drug development and commercialization in the fields of oncology and immune diseases and expands the global application of its core technology platforms through a diversified collaboration model. The company continues to integrate ESG into its business strategy and actively fulfill its social and environmental responsibilities while maintaining rapid growth. The report also mentions the specific measures and effectiveness of Wapatin Pharmaceuticals in governance, employee benefits, environmental protection, innovative R&D, supply chain management, etc., including employee training, health protection, pay benefits, and environmental and social risk management for suppliers. In addition, the company has made commitments to address climate change and set relevant management goals and measures.
AND PLATINUM PHARMACEUTICAL-B (02142.HK) PASSED ITS FOURTH ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT ON MARCH 28, 2024, SHOWCASING THE COMPANY'S EFFORTS AND ACHIEVEMENTS IN SOCIAL RESPONSIBILITY, ENVIRONMENTAL PROTECTION AND CORPORATE GOVERNANCE IN 2023. The report shows that in the face of a difficult external environment, Platinum Pharmaceuticals remains focused on innovative drug development and commercialization in the fields of oncology and immune diseases and expands the global application of its core technology platforms through a diversified collaboration model. The company continues to integrate ESG into its business strategy and actively fulfill its social and environmental responsibilities while maintaining rapid growth. The report also mentions the specific measures and effectiveness of Wapatin Pharmaceuticals in governance, employee benefits, environmental protection, innovative R&D, supply chain management, etc., including employee training, health protection, pay benefits, and environmental and social risk management for suppliers. In addition, the company has made commitments to address climate change and set relevant management goals and measures.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more